At inSoma Bio, we leverage nature’s own designs to develop unique products for reconstructive plastic surgery. Our investigational Fractomer™️ product, based on exciting technology out of Duke University, enables surgeons to use a person’s own tissue instead of synthetic implants and fillers to improve procedures like breast and facial reconstruction.
| Website | https://insomabio.com/ |
| Employees | 13 (7 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research, Biotechnology |
| Keywords | Plastic Surgery, Regenerative Medicine, Reconstructive Surgery, Tissue Regeneration, Tissue Engineering, Biomaterials, Surgical Materials, Medical Devices, Biotechnology, Skin Grafts, Surgical Implants, Biocompatible Materials, Medical Technology, Wound Healing, Orthopedic Biomaterials, Fracture Repair, Pharmaceutical, Dermal Fillers, Drug Delivery |
| Competitors | CRISPR Therapeutics, CureVac, bluebird bio, Verve Therapeutics, Intellia Therapeutics, Inc., Beam Therapeutics, Scribetx, Arcellx, Editas Medicine, Celsius Therapeutics +37 more (view full list) |
Looking for a particular inSoma Bio employee's phone or email?
Thalia Charles is the Vice President of Regulatory and Clinical Affairs of inSoma Bio.
7 people are employed at inSoma Bio.
inSoma Bio is based in Durham, North Carolina.